A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease - A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease

Dokkyo Medical University0 个研究点目标入组 64 人开始时间: 2016年5月10日最近更新: 2023年10月17日

试验速览

暂无简介。

•1)Patients with definitive or suspected mechanical obturation (intestinal obstruction attributable to tumor, hernia, etc.); 2)Patients with history of hypersensitivity to any of the ingredients of lubiprostone (Amitiza); 3)Patients with serious cardiovascular disease, lung disease, liver disease, renal disease, digestive disorder, neurological disorder, or psychiatric disorder (including pre-existing alcohol or drug abuse), or patients with a systemic disease; 4)Women who are pregnant, breast-feeding, or seeking to conceive or may conceive due to improper contraception method during the study period; 5)Patients receiving nonpharmacologic therapy within 4 weeks prior to the study commencement, which may influence the bowel movement; 6)Patients who received an investigational drug in other clinical study within 1 month prior to the study commencement (the period of which should be calculated based on the date on which the investigational drug was administered); 7)Patients who are otherwise ineligible to take part in the study as judged by Principal Investigator or other relevant person; or 8)Patients who meet the criteria concerning prohibited or restricted concomitant medications (i.e., drugs of the same class, or with interactions, etc.). 9)Patients with diarrhea 10)Patients of hypermagnesemia

发起方